Charles River Laboratories International, Inc.’s stock price dips to $165.80, marking a 4.66% decline: A deep dive into CRL’s performance

Charles River Laboratories International, Inc. (CRL)

165.80 USD -8.11 (-4.66%) Volume: 2.6M

Charles River Laboratories International, Inc.’s stock price is currently at 165.80 USD, experiencing a dip of -4.66% this trading session with a trading volume of 2.6M, reflecting a downward trend with a YTD percentage change of -10.42%. An in-depth analysis of CRL’s stock performance is key for potential investors.

Latest developments on Charles River Laboratories International, Inc.

Charles River Laboratories stock experienced a 6% decline today following a disappointing outlook for 2025, with concerns over potential suspension of NHP trade contributing to the drop. The company’s CEO revealed a drop in revenue outlook at a JP Morgan event, leading to a new 1-year low for the stock. Despite collaborations with Akron Bio to enhance operations and integration of CGMP materials into their cell therapy platform, Charles River Labs faced challenges that impacted their stock performance. Analysts at JPMorgan and BofA maintained a neutral stance on the stock due to revenue and margin headwinds, while TD Cowen expressed caution as the 2025 guide signals further declines. Overall, Charles River Laboratories stock fell on weak revenue projections and challenges in the market.

A look at Charles River Laboratories International, Inc. Smart Scores

Smart Score is a compound score for the Company indicating its overall outlook. It is derived by taking an equally weighted average of underlying Factor scores computed by Smartkarma

Charles River Laboratories International, Inc. is positioned for strong long-term growth according to Smartkarma Smart Scores. With high scores in Growth and Momentum, the company is expected to continue expanding and performing well in the future. Although its Value score is moderate, Charles River Laboratories‘ focus on providing research tools and support services for drug discovery and development positions it well in the market.

Despite a lower score in Dividend and Resilience, Charles River Laboratories International, Inc. remains a key player in providing essential animal research models for the development of new drugs, devices, and therapies. With a diverse customer base including pharmaceutical and biotechnology companies, hospitals, and academic institutions, the company is well-positioned to capitalize on the growing demand for research tools in the healthcare industry.

Disclaimer: This article by Smartkarma is general in nature and based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. Note that our articles may not factor in the latest price-sensitive company announcements or qualitative material.
While all reasonable care has been taken in the preparation, Smartkarma makes no assurance about the accuracy of any generated data or content. All content is indicative only and should be independently checked for accuracy and confirmed before use. Smartkarma accepts no responsibility for any loss or damage caused as a result of any inaccuracy or error within the Lab online tools or generated data.
Have feedback on this article? Concerned about the content? Get in touch with us directly.

💡 Before it’s here, it’s on Smartkarma